Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial

BACKGROUND: Safe and effective vaccines are urgently needed to end the COVID-19 pandemic caused by SARS-CoV-2 infection. We aimed to assess the preliminary safety, tolerability, and immunogenicity of an mRNA vaccine ARCoV, which encodes the SARS-CoV-2 spike protein receptor-binding domain (RBD). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Gui-Ling, Li, Xiao-Feng, Dai, Xia-Hong, Li, Nan, Cheng, Meng-Li, Huang, Zhen, Shen, Jian, Ge, Yu-Hua, Shen, Zhen-Wei, Deng, Yong-Qiang, Yang, Shu-Yuan, Zhao, Hui, Zhang, Na-Na, Zhang, Yi-Fei, Wei, Ling, Wu, Kai-Qi, Zhu, Meng-Fei, Peng, Cong-Gao, Jiang, Qi, Cao, Shou-Chun, Li, Yu-Hua, Zhao, Dan-Hua, Wu, Xiao-Hong, Ni, Ling, Shen, Hua-Hao, Dong, Chen, Ying, Bo, Sheng, Guo-Ping, Qin, Cheng-Feng, Gao, Hai-Nv, Li, Lan-Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786321/
https://www.ncbi.nlm.nih.gov/pubmed/35098177
http://dx.doi.org/10.1016/S2666-5247(21)00280-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786321/
https://www.ncbi.nlm.nih.gov/pubmed/35098177
http://dx.doi.org/10.1016/S2666-5247(21)00280-9

Ejemplares similares